Using single cell tracing of Crispr/Cas9 modified EGFR to express an EGFR-mVenus fusion protein, we validated the strong reduction of nEGFR in T47D (T47D-mVenus) breast cancer cells treated with cSNX1.3 compared to control cPTD4 treated cells (Fig. 1a). This evidence concerns the gene EGFR and breast cancer.